Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc.
TypePublic
NYSE: DNA (Class A)
IndustryBiotechnology
Founded2008 (2008) in Boston, Massachusetts, U.S.
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
Headquarters,
U.S.
Key people
  • Shyam Sankar (chairman)
  • Jason Kelly (CEO)
RevenueDecrease US$227 million (2024)
Negative increase US$−560 million (2024)
Negative increase US$−547 million (2024)
Total assetsDecrease US$1.38 billion (2024)
Total equityDecrease US$716 million (2024)
Number of employees
834 (2024)
Websiteginkgobioworks.com
Footnotes

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.